Sanofi hemophilia A drug lands breakthrough therapy designation 06-Jun-2022 By Jenni Spinner Efanesoctocog alfa is an investigational factor III therapy designed to prevent bleeds and bleeding episodes in patients diagnosed with the rare disorder.